BiotechTube
Dualsystems Biotech

Dualsystems Biotech

Zurich, Switzerland· Est.
dualsystems.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $13M

Overview

Dualsystems Biotech is a Zurich-based, private biotech service company focused on target identification for extracellular ligands. Its core technology, LRC-TriCEPS, allows for the covalent capture of ligand-receptor interactions on the surface of living cells, followed by mass spectrometry-based proteomics to identify binding partners. The company offers a three-step service workflow encompassing binding optimization (Pretest), target identification, and confirmation via siRNA knockdown. It generates revenue through collaborative research and service agreements with pharmaceutical and biotech companies, as evidenced by its multi-year partnership with aTyr Pharma.

AntibodiesBiologics

Technology Platform

LRC-TriCEPS and LRC-HATRIC: trifunctional chemical crosslinker platforms for covalent capture of ligand-receptor interactions on the surface of living cells, followed by enrichment and LC-MS/MS proteomics for target identification.

Funding History

3
Total raised:$13M
Seed$8M
Seed$2.5M
Grant$2.5M

Opportunities

Growing demand for target deconvolution in complex drug modalities like ADCs and biologics provides a strong market tailwind.
The company's ability to work with any cell type, including primary cells, positions it uniquely for physiologically relevant discovery, a key differentiator in the CRO landscape.
Multi-year collaborations, like the one with aTyr Pharma, provide stable revenue and validate the platform's utility for large-scale target identification campaigns.

Risk Factors

The service-based business model can lead to variable revenue streams and faces competition from other CROs with alternative target ID technologies.
Scientific risks include potential limitations of the glycan-dependent capture chemistry and the inherent challenges of false positives/negatives in complex proteomic workflows.
As a private, specialized player, scaling and maintaining technological superiority against potentially larger, well-funded competitors is an ongoing challenge.

Competitive Landscape

Dualsystems competes in the drug discovery services market, specifically in target identification and validation. Key competitors include other specialized CROs offering chemical proteomics (e.g., Cellzone/GSK legacy, certain mass spectrometry service labs), phage display, or protein microarray services. Its primary competitive advantage is the unique living-cell capture methodology, which contrasts with more common lysate-based or recombinant protein approaches. Larger, full-service CROs also offer target ID capabilities, but often as part of a broader suite of services.

More companies in Proteomics & Protein Engineering →More companies in Switzerland →